Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Vitamin D supplementation increased 25(OH)D levels significantly (mean difference [MD] = 2.01, 95% confidence intervals [CI]: 0.94 to 3.08, P < .05) and vitamin D supplementation had a significant effect on insulin resistance index (MD = −0.54, 95% CI: −1.28 to 0.20, P = .16), fasting glucose (MD = −0.59, 95% CI: −1.50 to 0.32, P = .20), and FINS levels (MD = −0.30, 95% CI: −0.77 to 0.17, P = .21) had no significant effect.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The effect of vitamin D supplementation on some metabolic parameters in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 8 RCTs

Source: Article title.

The effect of vitamin D supplementation on some metabolic parameters in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 8 RCTs

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

The effect of vitamin D supplementation on some metabolic parameters in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 8 RCTs

Systematic review · Medicine · 2023

Original publication title

The effect of vitamin D supplementation on some metabolic parameters in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 8 RCTs

Xuemeng Chen; Ye Zhao; Ran Zhang; Yan Zhao; Liheng Dai

Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Vitamin D supplementation improves 25(OH)D levels in patients with NAFLD, but there is no effect on HOMA-IR, FBG, or FINS.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Vitamin D is fat-soluble. It has effects in type 2 diabetes mellitus, metabolic syndrome, cardiovascular disease, cancer, and autoimmune diseases.[1] Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease of liver.[2] The incidence of NAFLD increases in the whole world.[3] Lifestyle interventions, dietary restrictions and physical exercise are recommended; however, the effects are usually limited and short-lived.[4] It shows that insulin resistance (IR), oxidative stress, and impaired glucolipid metabolism play a key role in the development of NAFLD; patient with NAFLD has a high risk of developing type 2 diabetes mellitus or metabolic syndrome.[5] Insulin resistance is the biggest contributor to this condition.[6] It shows that a reduced vitamin D level is strongly associated with the pathogenesis of IR, so vitamin D supplementation may have a significant improvement in glycemic control.[7] In pancreatic β-cells, 25-hydroxyvitamin D [25(OH)D] binds to the vitamin D receptor, which stimulates the insulin secretion.[8] Vitamin D in patients with NAFLD has controversial findings.

This study intends to conduct a systematic review and meta-analysis to clarify the role of vitamin D in patients with NAFLD.

Source: 1. Introduction

Study methods

What methods does the paper describe?

2.1. Search strategy

National Library of Medicine, Cochrane Library, China National Knowledge Infrastructure, Web of Science, WANFANG databases, and Google Scholar were retrieved to collect relevant randomized controlled trials (RCTs), which are published from the earliest records to April 2023. The search terms are “vitamin D,” “nonalcoholic fatty liver disease,” “vitamin D3,” “cholecalciferol,” “ergocalciferol,” “NAFLD” in combination. The literature screening process is shown in Figure 1.

Figure 1.

Literature screening process.

Figure image at the original source: open the original paper. This file is not included in this text import.

2.2. Inclusion criteria

(1) NAFLD or nonalcoholic steatohepatitis aged > 18 years; (2) placebo or lifestyle intervention in the control group, and oral or injectable vitamin D or D3 in the vitamin D group; (3) outcome indicators include the levels of 25(OH)D, homeostasis model assessment of insulin resistance (HOMA-IR), fasting blood glucose (FBG), and fasting insulin (FINS); (4) study design: RCTs.

2.3. Exclusion criteria

(1) Inaccessible abstracts or full text; (2) studies for which data could not be accurately extracted; (3) duplicate published studies.

2.4. Literature quality assessment

The evaluator first independently completes an initial screening of the included literature by reading the title and abstract. After reading the full text, literatures met the inclusion criteria were included. The following evaluation criteria for RCTs in Review Manager 5.4 were used: (1) generation of random sequences; (2) allocation concealment; (3) blinding of subjects and intervention providers; (4) blinding of outcome assessments; (5) completeness of outcome data; (6) selective outcome reporting; and (7) other biases. The 7 items above were evaluated using “low risk,” “high risk,” and “uncertain risk.”

2.5. Data extraction

Data extracted from the included literatures included the following: (1) general information such as title, first author, year of publication, sample size and trial quality score; (2) comparability of data and interventions across patient data groups; and (3) outcome indicators: levels of 25(OH)D, HOMA-IR, FBG and FINS.

2.6. Statistical processing

Data were analyzed using Review Manager 5.4 software at a test level of α = 0.05. Continuous variables and units were analyzed by mean difference (MD) and its 95% confidence intervals (CI). Clinical heterogeneity of included studies was first analyzed, followed by statistical heterogeneity using the I2 test.[9] When P > .1, I2 < 50%, homogeneity among several similar studies could be considered and a fixed-effects model was chosen for meta-analysis. Heterogeneity was considered when P < .1, I2 > 50%; and a random-effect model was used. P < .05 indicates a statistically significant difference and I2 ≥ 50% suggests high heterogeneity.[10]

Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods

Results: Study characteristics

Figure 2 is the flow chart. The initial review obtained 535 papers, and finally 8 RCTs are included.[11Not reported18] There are 657 patients totally. 329 patients are in the control group and 328 patients are in the experimental group. The basic characteristics of includes studies are shown in Table 1.

Table 1

Basic information of inclusion in the study.

AuthorNumber of patientsVitamin D supplementation dosePeriodicityCross referencing measuresStudy outcome indicators
Hamid L (2016)T:40
C:40
25 μg/d12 weekPlacebo①②③④
Hamid Y (2021)T:64
C:64
0.25 μg/d17 weekPlacebo①②③
Mahdi (2014)T:30
C:30
5000 U/w10 weekPlacebo④
Mazhar (2019)T:51
C:51
5000 U/w12 weekPlacebo①④
Dai Jiale (2022)T:50
C:50
400 U/d12 weekLifestyle interventions①②③④
Han Yuanping (2022)T:14
C:15
Single intramuscular injection of vitamin
Vitamin D3 600,000 U
1 monthNo intervention③
Li Jinqiang (2022)T:42
C:42
0.25 μg/d12 weekLifestyle interventions④
Lu Yongwen (2019)T:37
C:37
0.5 μg/d12 weekLifestyle interventions①②③④

① Insulin resistance index. ② Fasting blood glucose. ③ Insulin level. ④ 25(OH)D.

C = control group, T = test group.

Figure 2.

Flow chart.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: 3.1. Study characteristics Source: 3.1. Study characteristics Source: 3.1. Study characteristics

Results: Quality assessment

All 8 studies are low risk according to the randomized allocation. Seven studies are low risk and one study is unclear in the allocation concealment. Three studies are low risk and 5 studies are unclear in the double-blind method. Two studies are low risk and 6 studies are unclear in the evaluation of blindness. Four studies are low risk and 4 studies are unclear in the data integrity. Five studies are low risk and 3 studies are unclear in the selective report.

Six studies are low risk and 2 studies are unclear in the others. Since there is no high risk in these 7 criteria, the quality of all included studies is good. The quality assessment table is shown in Table 2.

Table 2

Quality assessment table.

Included studiesRandom allocationAllocation concealmentDouble blind methodEvaluation of blindnessData integritySelective reportOthers
Hamid L (2016)Low riskLow riskUnclearUnclearLow riskUnclearLow risk
Hamid Y (2021)Low riskLow riskLow riskLow riskUnclearLow riskLow risk
Mahdi (2014)Low riskLow riskLow riskLow riskLow riskUnclearLow risk
Mazhar (2019)Low riskLow riskLow riskUnclearUnclearLow riskUnclear
Dai Jiale (2022)Low riskUnclearUnclearUnclearLow riskLow riskUnclear
Han Yuanping (2022)Low riskLow riskUnclearUnclearLow riskUnclearLow risk
Li Jinqiang (2022)Low riskLow riskUnclearUnclearUnclearLow riskLow risk
Lu Yongwen (2019)Low riskLow riskUnclearUnclearUnclearLow riskLow risk
Source: 3.2. Quality assessment Source: 3.2. Quality assessment

Results: Meta-analysis results

3.3.1. 25(OH)D.

Six studies report changes in 25(OH)D in patients. The results are shown in Figure 3. There is a heterogeneity as I2 = 96% and a random-effect model was used. Under a leave-one-out approach, the heterogeneity is possibly caused by the research of Mahdi (Fig. 4). Vitamin D supplementation significantly increased serum 25(OH)D levels (MD = 2.01, 95% CI: 0.94 to 3.08, P < .05).

Figure 3.

Changes of 25(OH)D between 2 groups. 25(OH)D = 25-hydroxyvitamin D.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 4.

Effect sizes of 25(OH)D under leave-one-out approach. 25(OH)D = 25-hydroxyvitamin D.

Figure image at the original source: open the original paper. This file is not included in this text import.

3.3.2. HOMA-IR.

Five studies are included. The results are shown in Figure 5. There is a heterogeneity as I2 = 92% and a random-effect model was used. Under a leave-one-out approach, the heterogeneity is possibly caused by the research of Hamind L and Hamind Y (Fig. 6). There is no statistically significant difference in the effect of vitamin D supplementation on HOMA-IR (MD = -0.54, 95% CI: -1.28 to 0.20, P = .16).

Figure 5.

Changes of HOMA-IR between 2 groups. HOMA-IR = homeostasis model assessment of insulin resistance.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 6.

Effect sizes of HOMA-IR under leave-one-out approach. HOMA-IR = homeostasis model assessment of insulin resistance.

Figure image at the original source: open the original paper. This file is not included in this text import.

3.3.3. FBG.

Four studies are included. The results are shown in Figure 7. There is a heterogeneity as I2 = 94% and a random-effect model was used. Under a leave-one-out approach, the heterogeneity is possibly caused by the research of Hamind L and Hamind Y (Fig. 8). There is no statistically significant difference in the effect of vitamin D supplementation on FBG (MD = −0.59, 95% CI: −1.50 to 0.32, P = .20).

Figure 7.

Changes of FBG between 2 groups. FBG = fasting blood glucose.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 8.

Effect sizes of FBG under leave-one-out approach. FBG = fasting blood glucose.

Figure image at the original source: open the original paper. This file is not included in this text import.

3.3.4. FINS.

Five studies are included. The results are shown in Figure 9. There is a heterogeneity as I2 = 81% and a random-effect model was used. Under a leave-one-out approach, the heterogeneity is possibly caused by the research of Hamind L and Han (Fig. 10). There is no statistically significant difference in the effect of vitamin D supplementation on FINS (MD = −0.30, 95% CI: −0.77 to 0.17, P = .21).

Figure 9.

Changes of FINS between 2 groups. FINS = fasting insulin levels.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 10.

Effect sizes of FINS under leave-one-out approach. FINS = fasting insulin levels.

Figure image at the original source: open the original paper. This file is not included in this text import.

3.3.5. Publication bias.

As shown in Figure 11, based on the 25(OH)D level, funnel plot is applied to evaluate the publication biases of 6 studies. It shows that the publication bias is small.

Figure 11.

Funnel plot.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: 3.3. Meta-analysis results Source: 3.3. Meta-analysis results Source: 3.3. Meta-analysis results Source: 3.3. Meta-analysis results Source: 3.3. Meta-analysis results

Discussion

In this meta-analysis, vitamin D supplementation increased 25(OH)D levels significantly. However, there is no significant effect on HOMA-IR, FBG, or FINS. Also, heterogeneity exists in all indicators. In the included studies, patients in both groups have only placebo and lifestyle interventions without taking statins or any other medicines. The reason for no treatment of statins in related RCTs is probably that statins have no influence on plasma vitamin D levels.[19]

Since 25(OH)D has a half-life of approximately 3 weeks, heterogeneity within the HOMA-IR group disappears and FINS reduces when the duration of administration is prolonged (>16 weeks).[4] It suggests that vitamin D supplementation in improving IR is based on a low baseline level of vitamin D, so vitamin D sufficiency may lead to a relative insensitivity to vitamin D supplementation.[20] In addition, a recent RCT suggests that vitamin D supplementation may not improve glycemic index or anthropometry in patients with NAFLD.[21] It found that 25(OH) D levels are lower in the NAFLD group than in the control group, thus suggesting a negative correlation between 25(OH) D levels and NAFLD.[1] A meta-analysis shows that lower serum 25(OH)D concentrations (mainly in patients with vitamin D deficiency) are the only significant predictor of NAFLD.[22] These are generally consistent with the findings in this meta-analysis.

This meta-analysis focuses on assessing indexes related to glucose metabolism but not liver enzymes or lipids. Active vitamin D is excluded from this study, since supplementation of active vitamin D cannot increase circulating levels of 25(OH)D. In extrarenal tissues, free 25(OH)D metabolized by 1-alpha-hydroxylase to 1,25(OH)2D, then it binds to the vitamin D receptor to regulate gene transcription and perform physiological functions.[23]

This study has some limitations: (1) the number of populations included in the study is relatively small; (2) there is heterogeneity, which may be related to duration of dosing, route of administration and the differences within baseline levels of 25(OH)D.

Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion

Results

3.1. Study characteristics

Figure 2 is the flow chart. The initial review obtained 535 papers, and finally 8 RCTs are included.[11Not reported18] There are 657 patients totally. 329 patients are in the control group and 328 patients are in the experimental group. The basic characteristics of includes studies are shown in Table 1.

Table 1

Basic information of inclusion in the study.

AuthorNumber of patientsVitamin D supplementation dosePeriodicityCross referencing measuresStudy outcome indicators
Hamid L (2016)T:40
C:40
25 μg/d12 weekPlacebo①②③④
Hamid Y (2021)T:64
C:64
0.25 μg/d17 weekPlacebo①②③
Mahdi (2014)T:30
C:30
5000 U/w10 weekPlacebo④
Mazhar (2019)T:51
C:51
5000 U/w12 weekPlacebo①④
Dai Jiale (2022)T:50
C:50
400 U/d12 weekLifestyle interventions①②③④
Han Yuanping (2022)T:14
C:15
Single intramuscular injection of vitamin
Vitamin D3 600,000 U
1 monthNo intervention③
Li Jinqiang (2022)T:42
C:42
0.25 μg/d12 weekLifestyle interventions④
Lu Yongwen (2019)T:37
C:37
0.5 μg/d12 weekLifestyle interventions①②③④

① Insulin resistance index. ② Fasting blood glucose. ③ Insulin level. ④ 25(OH)D.

C = control group, T = test group.

Figure 2.

Flow chart.

Figure image at the original source: open the original paper. This file is not included in this text import.

3.2. Quality assessment

All 8 studies are low risk according to the randomized allocation. Seven studies are low risk and one study is unclear in the allocation concealment. Three studies are low risk and 5 studies are unclear in the double-blind method. Two studies are low risk and 6 studies are unclear in the evaluation of blindness. Four studies are low risk and 4 studies are unclear in the data integrity. Five studies are low risk and 3 studies are unclear in the selective report.

Six studies are low risk and 2 studies are unclear in the others. Since there is no high risk in these 7 criteria, the quality of all included studies is good. The quality assessment table is shown in Table 2.

Table 2

Quality assessment table.

Included studiesRandom allocationAllocation concealmentDouble blind methodEvaluation of blindnessData integritySelective reportOthers
Hamid L (2016)Low riskLow riskUnclearUnclearLow riskUnclearLow risk
Hamid Y (2021)Low riskLow riskLow riskLow riskUnclearLow riskLow risk
Mahdi (2014)Low riskLow riskLow riskLow riskLow riskUnclearLow risk
Mazhar (2019)Low riskLow riskLow riskUnclearUnclearLow riskUnclear
Dai Jiale (2022)Low riskUnclearUnclearUnclearLow riskLow riskUnclear
Han Yuanping (2022)Low riskLow riskUnclearUnclearLow riskUnclearLow risk
Li Jinqiang (2022)Low riskLow riskUnclearUnclearUnclearLow riskLow risk
Lu Yongwen (2019)Low riskLow riskUnclearUnclearUnclearLow riskLow risk

3.3. Meta-analysis results

3.3.1. 25(OH)D.

Six studies report changes in 25(OH)D in patients. The results are shown in Figure 3. There is a heterogeneity as I2 = 96% and a random-effect model was used. Under a leave-one-out approach, the heterogeneity is possibly caused by the research of Mahdi (Fig. 4). Vitamin D supplementation significantly increased serum 25(OH)D levels (MD = 2.01, 95% CI: 0.94 to 3.08, P < .05).

Figure 3.

Changes of 25(OH)D between 2 groups. 25(OH)D = 25-hydroxyvitamin D.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 4.

Effect sizes of 25(OH)D under leave-one-out approach. 25(OH)D = 25-hydroxyvitamin D.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.3.2. HOMA-IR.

Five studies are included. The results are shown in Figure 5. There is a heterogeneity as I2 = 92% and a random-effect model was used. Under a leave-one-out approach, the heterogeneity is possibly caused by the research of Hamind L and Hamind Y (Fig. 6). There is no statistically significant difference in the effect of vitamin D supplementation on HOMA-IR (MD = -0.54, 95% CI: -1.28 to 0.20, P = .16).

Figure 5.

Changes of HOMA-IR between 2 groups. HOMA-IR = homeostasis model assessment of insulin resistance.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 6.

Effect sizes of HOMA-IR under leave-one-out approach. HOMA-IR = homeostasis model assessment of insulin resistance.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.3.3. FBG.

Four studies are included. The results are shown in Figure 7. There is a heterogeneity as I2 = 94% and a random-effect model was used. Under a leave-one-out approach, the heterogeneity is possibly caused by the research of Hamind L and Hamind Y (Fig. 8). There is no statistically significant difference in the effect of vitamin D supplementation on FBG (MD = −0.59, 95% CI: −1.50 to 0.32, P = .20).

Figure 7.

Changes of FBG between 2 groups. FBG = fasting blood glucose.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 8.

Effect sizes of FBG under leave-one-out approach. FBG = fasting blood glucose.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.3.4. FINS.

Five studies are included. The results are shown in Figure 9. There is a heterogeneity as I2 = 81% and a random-effect model was used. Under a leave-one-out approach, the heterogeneity is possibly caused by the research of Hamind L and Han (Fig. 10). There is no statistically significant difference in the effect of vitamin D supplementation on FINS (MD = −0.30, 95% CI: −0.77 to 0.17, P = .21).

Figure 9.

Changes of FINS between 2 groups. FINS = fasting insulin levels.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 10.

Effect sizes of FINS under leave-one-out approach. FINS = fasting insulin levels.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.3.5. Publication bias.

As shown in Figure 11, based on the 25(OH)D level, funnel plot is applied to evaluate the publication biases of 6 studies. It shows that the publication bias is small.

Figure 11.

Funnel plot.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: 3. Results Source: 3. Results Source: 3. Results

Conclusion

Vitamin D supplementation improves 25(OH)D levels in patients with NAFLD, but there is no effect on HOMA-IR, FBG, or FINS.

Source: 5. Conclusion
Authors’ abstract

Background:

To systematically evaluate the effects of vitamin D supplementation in patients with nonalcoholic fatty liver disease (NAFLD).

Methods:

National Library of Medicine, Cochrane Library, Elsevier, China National Knowledge Infrastructure, Web of Science, WANFANG databases, and Google Scholar were retrieved to collect relevant randomized controlled trials, which are published from the earliest records the time the database was created to April 2023. Meta-analysis was conducted by using Review Manager 5.4 software after evaluating in terms of inclusion and exclusion criteria. The outcome indicators include 25-hydroxyvitamin D [25(OH)D] levels, insulin resistance index (homeostasis model assessment of insulin resistance), fasting blood glucose, and fasting insulin levels (FINS).

Results:

Eight randomized controlled trials with a total of 657 patients are included. Vitamin D supplementation increased 25(OH)D levels significantly (mean difference [MD] = 2.01, 95% confidence intervals [CI]: 0.94 to 3.08, P < .05) and vitamin D supplementation had a significant effect on insulin resistance index (MD = −0.54, 95% CI: −1.28 to 0.20, P = .16), fasting glucose (MD = −0.59, 95% CI: −1.50 to 0.32, P = .20), and FINS levels (MD = −0.30, 95% CI: −0.77 to 0.17, P = .21) had no significant effect.

Conclusion:

Vitamin D supplementation improves 25(OH)D levels in patients with nonalcoholic fatty liver disease, but there is no effect on homeostasis model assessment of insulin resistance, fasting blood glucose, or FINS.

Read the full paper

1. Introduction

Vitamin D is fat-soluble. It has effects in type 2 diabetes mellitus, metabolic syndrome, cardiovascular disease, cancer, and autoimmune diseases.[1] Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease of liver.[2] The incidence of NAFLD increases in the whole world.[3] Lifestyle interventions, dietary restrictions and physical exercise are recommended; however, the effects are usually limited and short-lived.[4] It shows that insulin resistance (IR), oxidative stress, and impaired glucolipid metabolism play a key role in the development of NAFLD; patient with NAFLD has a high risk of developing type 2 diabetes mellitus or metabolic syndrome.[5] Insulin resistance is the biggest contributor to this condition.[6] It shows that a reduced vitamin D level is strongly associated with the pathogenesis of IR, so vitamin D supplementation may have a significant improvement in glycemic control.[7] In pancreatic β-cells, 25-hydroxyvitamin D [25(OH)D] binds to the vitamin D receptor, which stimulates the insulin secretion.[8] Vitamin D in patients with NAFLD has controversial findings.

This study intends to conduct a systematic review and meta-analysis to clarify the role of vitamin D in patients with NAFLD.

2. Materials and Methods

2.1. Search strategy

National Library of Medicine, Cochrane Library, China National Knowledge Infrastructure, Web of Science, WANFANG databases, and Google Scholar were retrieved to collect relevant randomized controlled trials (RCTs), which are published from the earliest records to April 2023. The search terms are “vitamin D,” “nonalcoholic fatty liver disease,” “vitamin D3,” “cholecalciferol,” “ergocalciferol,” “NAFLD” in combination. The literature screening process is shown in Figure 1.

Figure 1.

Literature screening process.

Figure image at the original source: open the original paper. This file is not included in this text import.

2.2. Inclusion criteria

(1) NAFLD or nonalcoholic steatohepatitis aged > 18 years; (2) placebo or lifestyle intervention in the control group, and oral or injectable vitamin D or D3 in the vitamin D group; (3) outcome indicators include the levels of 25(OH)D, homeostasis model assessment of insulin resistance (HOMA-IR), fasting blood glucose (FBG), and fasting insulin (FINS); (4) study design: RCTs.

2.3. Exclusion criteria

(1) Inaccessible abstracts or full text; (2) studies for which data could not be accurately extracted; (3) duplicate published studies.

2.4. Literature quality assessment

The evaluator first independently completes an initial screening of the included literature by reading the title and abstract. After reading the full text, literatures met the inclusion criteria were included. The following evaluation criteria for RCTs in Review Manager 5.4 were used: (1) generation of random sequences; (2) allocation concealment; (3) blinding of subjects and intervention providers; (4) blinding of outcome assessments; (5) completeness of outcome data; (6) selective outcome reporting; and (7) other biases. The 7 items above were evaluated using “low risk,” “high risk,” and “uncertain risk.”

2.5. Data extraction

Data extracted from the included literatures included the following: (1) general information such as title, first author, year of publication, sample size and trial quality score; (2) comparability of data and interventions across patient data groups; and (3) outcome indicators: levels of 25(OH)D, HOMA-IR, FBG and FINS.

2.6. Statistical processing

Data were analyzed using Review Manager 5.4 software at a test level of α = 0.05. Continuous variables and units were analyzed by mean difference (MD) and its 95% confidence intervals (CI). Clinical heterogeneity of included studies was first analyzed, followed by statistical heterogeneity using the I2 test.[9] When P > .1, I2 < 50%, homogeneity among several similar studies could be considered and a fixed-effects model was chosen for meta-analysis. Heterogeneity was considered when P < .1, I2 > 50%; and a random-effect model was used. P < .05 indicates a statistically significant difference and I2 ≥ 50% suggests high heterogeneity.[10]

3. Results

3.1. Study characteristics

Figure 2 is the flow chart. The initial review obtained 535 papers, and finally 8 RCTs are included.[11Not reported18] There are 657 patients totally. 329 patients are in the control group and 328 patients are in the experimental group. The basic characteristics of includes studies are shown in Table 1.

Table 1

Basic information of inclusion in the study.

AuthorNumber of patientsVitamin D supplementation dosePeriodicityCross referencing measuresStudy outcome indicators
Hamid L (2016)T:40
C:40
25 μg/d12 weekPlacebo①②③④
Hamid Y (2021)T:64
C:64
0.25 μg/d17 weekPlacebo①②③
Mahdi (2014)T:30
C:30
5000 U/w10 weekPlacebo④
Mazhar (2019)T:51
C:51
5000 U/w12 weekPlacebo①④
Dai Jiale (2022)T:50
C:50
400 U/d12 weekLifestyle interventions①②③④
Han Yuanping (2022)T:14
C:15
Single intramuscular injection of vitamin
Vitamin D3 600,000 U
1 monthNo intervention③
Li Jinqiang (2022)T:42
C:42
0.25 μg/d12 weekLifestyle interventions④
Lu Yongwen (2019)T:37
C:37
0.5 μg/d12 weekLifestyle interventions①②③④

① Insulin resistance index. ② Fasting blood glucose. ③ Insulin level. ④ 25(OH)D.

C = control group, T = test group.

Figure 2.

Flow chart.

Figure image at the original source: open the original paper. This file is not included in this text import.

3.2. Quality assessment

All 8 studies are low risk according to the randomized allocation. Seven studies are low risk and one study is unclear in the allocation concealment. Three studies are low risk and 5 studies are unclear in the double-blind method. Two studies are low risk and 6 studies are unclear in the evaluation of blindness. Four studies are low risk and 4 studies are unclear in the data integrity. Five studies are low risk and 3 studies are unclear in the selective report.

Six studies are low risk and 2 studies are unclear in the others. Since there is no high risk in these 7 criteria, the quality of all included studies is good. The quality assessment table is shown in Table 2.

Table 2

Quality assessment table.

Included studiesRandom allocationAllocation concealmentDouble blind methodEvaluation of blindnessData integritySelective reportOthers
Hamid L (2016)Low riskLow riskUnclearUnclearLow riskUnclearLow risk
Hamid Y (2021)Low riskLow riskLow riskLow riskUnclearLow riskLow risk
Mahdi (2014)Low riskLow riskLow riskLow riskLow riskUnclearLow risk
Mazhar (2019)Low riskLow riskLow riskUnclearUnclearLow riskUnclear
Dai Jiale (2022)Low riskUnclearUnclearUnclearLow riskLow riskUnclear
Han Yuanping (2022)Low riskLow riskUnclearUnclearLow riskUnclearLow risk
Li Jinqiang (2022)Low riskLow riskUnclearUnclearUnclearLow riskLow risk
Lu Yongwen (2019)Low riskLow riskUnclearUnclearUnclearLow riskLow risk

3.3. Meta-analysis results

3.3.1. 25(OH)D.

Six studies report changes in 25(OH)D in patients. The results are shown in Figure 3. There is a heterogeneity as I2 = 96% and a random-effect model was used. Under a leave-one-out approach, the heterogeneity is possibly caused by the research of Mahdi (Fig. 4). Vitamin D supplementation significantly increased serum 25(OH)D levels (MD = 2.01, 95% CI: 0.94 to 3.08, P < .05).

Figure 3.

Changes of 25(OH)D between 2 groups. 25(OH)D = 25-hydroxyvitamin D.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 4.

Effect sizes of 25(OH)D under leave-one-out approach. 25(OH)D = 25-hydroxyvitamin D.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.3.2. HOMA-IR.

Five studies are included. The results are shown in Figure 5. There is a heterogeneity as I2 = 92% and a random-effect model was used. Under a leave-one-out approach, the heterogeneity is possibly caused by the research of Hamind L and Hamind Y (Fig. 6). There is no statistically significant difference in the effect of vitamin D supplementation on HOMA-IR (MD = -0.54, 95% CI: -1.28 to 0.20, P = .16).

Figure 5.

Changes of HOMA-IR between 2 groups. HOMA-IR = homeostasis model assessment of insulin resistance.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 6.

Effect sizes of HOMA-IR under leave-one-out approach. HOMA-IR = homeostasis model assessment of insulin resistance.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.3.3. FBG.

Four studies are included. The results are shown in Figure 7. There is a heterogeneity as I2 = 94% and a random-effect model was used. Under a leave-one-out approach, the heterogeneity is possibly caused by the research of Hamind L and Hamind Y (Fig. 8). There is no statistically significant difference in the effect of vitamin D supplementation on FBG (MD = −0.59, 95% CI: −1.50 to 0.32, P = .20).

Figure 7.

Changes of FBG between 2 groups. FBG = fasting blood glucose.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 8.

Effect sizes of FBG under leave-one-out approach. FBG = fasting blood glucose.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.3.4. FINS.

Five studies are included. The results are shown in Figure 9. There is a heterogeneity as I2 = 81% and a random-effect model was used. Under a leave-one-out approach, the heterogeneity is possibly caused by the research of Hamind L and Han (Fig. 10). There is no statistically significant difference in the effect of vitamin D supplementation on FINS (MD = −0.30, 95% CI: −0.77 to 0.17, P = .21).

Figure 9.

Changes of FINS between 2 groups. FINS = fasting insulin levels.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 10.

Effect sizes of FINS under leave-one-out approach. FINS = fasting insulin levels.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.3.5. Publication bias.

As shown in Figure 11, based on the 25(OH)D level, funnel plot is applied to evaluate the publication biases of 6 studies. It shows that the publication bias is small.

Figure 11.

Funnel plot.

Figure image at the original source: open the original paper. This file is not included in this text import.

4. Discussion

In this meta-analysis, vitamin D supplementation increased 25(OH)D levels significantly. However, there is no significant effect on HOMA-IR, FBG, or FINS. Also, heterogeneity exists in all indicators. In the included studies, patients in both groups have only placebo and lifestyle interventions without taking statins or any other medicines. The reason for no treatment of statins in related RCTs is probably that statins have no influence on plasma vitamin D levels.[19]

Since 25(OH)D has a half-life of approximately 3 weeks, heterogeneity within the HOMA-IR group disappears and FINS reduces when the duration of administration is prolonged (>16 weeks).[4] It suggests that vitamin D supplementation in improving IR is based on a low baseline level of vitamin D, so vitamin D sufficiency may lead to a relative insensitivity to vitamin D supplementation.[20] In addition, a recent RCT suggests that vitamin D supplementation may not improve glycemic index or anthropometry in patients with NAFLD.[21] It found that 25(OH) D levels are lower in the NAFLD group than in the control group, thus suggesting a negative correlation between 25(OH) D levels and NAFLD.[1] A meta-analysis shows that lower serum 25(OH)D concentrations (mainly in patients with vitamin D deficiency) are the only significant predictor of NAFLD.[22] These are generally consistent with the findings in this meta-analysis.

This meta-analysis focuses on assessing indexes related to glucose metabolism but not liver enzymes or lipids. Active vitamin D is excluded from this study, since supplementation of active vitamin D cannot increase circulating levels of 25(OH)D. In extrarenal tissues, free 25(OH)D metabolized by 1-alpha-hydroxylase to 1,25(OH)2D, then it binds to the vitamin D receptor to regulate gene transcription and perform physiological functions.[23]

This study has some limitations: (1) the number of populations included in the study is relatively small; (2) there is heterogeneity, which may be related to duration of dosing, route of administration and the differences within baseline levels of 25(OH)D.

5. Conclusion

Vitamin D supplementation improves 25(OH)D levels in patients with NAFLD, but there is no effect on HOMA-IR, FBG, or FINS.

Acknowledgments

The authors thank Dr Bin Wang for assistance with data extraction.

Author contributions

Conceptualization: Xuemeng Chen, Ye Zhao, Yan Zhao.

Funding acquisition: Ye Zhao, Liheng Dai.

Investigation: Xuemeng Chen.

Methodology: Liheng Dai.

Project administration: Ran Zhang.

Resources: Ye Zhao, Yan Zhao.

Supervision: Liheng Dai.

Validation: Yan Zhao, Liheng Dai.

Writing: original draft: Xuemeng Chen, Ye Zhao.

Writing: review & editing: Ran Zhang, Yan Zhao, Liheng Dai.

Abbreviations:

25(OH)D

25-hydroxy vitamin D

CI

confidence intervals

FBG

fasting blood glucose

FINS

fasting insulin

HOMA-IR

homeostasis model assessment of insulin resistance

IR

insulin resistance

MD

mean difference

NAFLD

nonalcoholic fatty liver disease

RCT

randomized controlled trial

This project was supported by the Krirk University Science Foundation for Young Scholars: 2022 (107).

The authors have no conflicts of interest to disclose.

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

How to cite this article: Chen X, Zhao Y, Zhang R, Zhao Y, Dai L. The effect of vitamin D supplementation on some metabolic parameters in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 8 RCTs. Medicine 2023;102:42(e35717).

References

[1] Li L . Correlation analysis of serum 25(OH)D and non-alcoholic fatty liver in physical examiners. Inner Mongolia Med J . 2021 ;53 :776Not reported9 .
[2] Lian CY Zhai ZZ Li ZF . High fat diet-triggered non-alcoholic fatty liver disease: a review of proposed mechanisms. Chem Biol Interact . 2020 ;330 :109199 . 32805210 10.1016/j.cbi.2020.109199
[3] Carlsson B Lindén D Brolén G . Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther . 2020 ;51 :1305Not reported20 . 32383295 10.1111/apt.15738 PMC7318322
[4] Guo L Cao J Chen Y . A meta-analysis of the effect of vitamin D supplementation on glucose metabolism-related indicators in patients with nonalcoholic fatty liver disease. J Clin Pharmacother . 2022 ;20 :59Not reported65 .
[5] Yu TP Zhao TC Chen MY . Relationship between nonalcoholic fatty liver and metabolic syndrome in adult patients with occult autoimmune diabetes mellitus. Chin Med J (Engl) . 2018 ;98 :2398Not reported402 . 10.3760/cma.j.issn.0376-2491.2018.30.006 30138983
[6] Armandi A Schattenberg JM . Beyond the paradigm of weight loss in non-alcoholic fatty liver disease: from pathophysiology to novel dietary approaches. Nutrients . 2021 ;13 :1977 . 34201382 10.3390/nu13061977 PMC8226973
[7] Li X Liu Y Zheng Y . The effect of vitamin D supplementation on glycemic control in type 2 diabetes patients: a systematic review and meta-analysis. Nutrients . 2018 ;10 :375 . 29562681 10.3390/nu10030375 PMC5872793
[8] Raza S Tewari A Rajak S . Vitamins and non-alcoholic fatty liver disease: a molecular insight. Liver Res . 2021 ;5 :62Not reported71 . 34221537 10.1016/j.livres.2021.03.004 PMC7611112
[9] Cordero CP Dans AL . Key concepts in clinical epidemiology: detecting and dealing with heterogeneity in meta-analyses. J Clin Epidemiol . 2021 ;130 :149Not reported51 . 33483004 10.1016/j.jclinepi.2020.09.045
[10] Khan MS Li L Yasmin F . Assessment of heterogeneity in heart failure-related meta-analyses. Circ Heart Fail . 2020 ;13 :e007070 . 33131285 10.1161/CIRCHEARTFAILURE.120.007070
[11] Dai J Xu H Wang J . Effects of vitamin D supplementation on insulin resistance and inflammatory factor levels in patients with nonalcoholic fatty liver disease. Chin Pharm . 2022 ;25 :458Not reported61 .
[12] Lu YW . Effect of vitamin D supplementation on insulin resistance in nonalcoholic fatty liver. Chin Foreign Med Res . 2019 ;17 :39Not reported41 .
[13] Han Y Xu S Jiang X . Effect of vitamin D supplementation on intestinal flora in patients with nonalcoholic fatty liver disease. J South China Univ Technol Nat Sci Ed . 2022 ;50 :62Not reported73 .
[14] Li J Wang H Xie Q . Effects of vitamin D supplementation therapy on biochemical indices, IL-18, IL-37 and liver fibrosis and steatosis in patients with non-alcoholic steatohepatitis. J Hunan Normal Univ Med Ed . 2022 ;19 :117Not reported20 .
[15] Yaghooti H Ghanavati F Seyedian SS . The efficacy of calcitriol treatment in non-alcoholic fatty liver patients with different genotypes of vitamin D receptor FokI polymorphism. BMC Pharmacol Toxicol . 2021 ;22 :18 . 33827700 10.1186/s40360-021-00485-y PMC8028246
[16] Hussain M Iqbal J Malik SA . Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pak J Pharm Sci . 2019 ;32 (3 Special ):1343Not reported8 . 31551213
[17] Lorvand Amiri H Agah S Mousavi SN . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Arch Iran Med . 2016 ;19 :631Not reported8 . 27631178
[18] Foroughi M Maghsoudi Z Ghiasvand R . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. Int J Prev Med . 2014 ;5 :969Not reported75 . 25489444 PMC4258669
[19] Sahebkar A Reiner Z Simental-Mendia LE . Impact of statin therapy on plasma vitamin D levels: a systematic review and meta-analysis. Curr Pharm Des . 2017 ;23 :861Not reported9 . 27719645 10.2174/1381612822666161006150542
[20] Zou J Wang Y Wang Y . Research progress of vitamin D to improve insulin resistance. China Pharm . 2023 ;32 :127Not reported32 .
[21] Hariri M Zohdi S . Effect of vitamin D on nonalcoholic fatty liver disease: a systematic review of randomized controlled clinical trials. Int J Prev Med . 2019 ;10 :14 . 30774848 10.4103/ijpvm.IJPVM_499_17 PMC6360993
[22] Gad AI Elmedames MR Abdelhai AR . Efficacy of vitamin D supplementation on adult patients with non-alcoholic fatty liver disease: a single-center experience. Gastroenterol Hepatol Bed Bench . 2021 ;14 :44Not reported52 . 33868609 PMC8035533
[23] Bouillon R Marcocci C Carmeliet G . Skeletal and ex-traskeletal actions of vitamin D: current evidence and out-standing questions. Endocr Rev . 2019 ;40 :1109Not reported51 . 30321335 10.1210/er.2018-00126 PMC6626501
Publication and source details

Original title: The effect of vitamin D supplementation on some metabolic parameters in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 8 RCTs

Xuemeng Chen; Ye Zhao; Ran Zhang; Yan Zhao; Liheng Dai

Medicine · 2023

* Correspondence: Liheng Dai, Department of Internal Medicine, Tianjin Beichen Traditional Chinese Medicine Hospital, Tianjin 300400, China (e-mail: dailiheng2023@163.com).Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.2023https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T05:57:46.895616+00:00

DOI: 10.1097/md.0000000000035717 · PMC10589544